TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23064478

Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (onabotulinumtoxinA; 140-200 units) injections into the pectoralis major with or without injections to the teres major
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo (saline) injections
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (onabotulinumtoxinA; 140-200 units) injections
Number of subjects: 37
Study: 20103445

Group type: EXPERIMENTAL
Intervention: Continuous regimen of ethinylestradiol (30 mcg) and drospirenone (3 mg) for 168 days
Number of subjects: 78

Group type: COMPARATOR
Intervention: Traditional cyclic regimen of ethinylestradiol (30 mcg) and drospirenone (3 mg) for six 28-day cycles with a 7-day hormone-free interval
Number of subjects: 78
Study: 18806012

Group type: EXPERIMENTAL
Intervention: Clevidipine (CLV)
Number of subjects: 1512

Group type: COMPARATOR
Intervention: Sodium nitroprusside (SNP)
Number of subjects: 1512
Study: 15694572

Group type: EXPERIMENTAL
Intervention: Single course of hylan G-F 20
Number of subjects: 255

Group type: EXPERIMENTAL
Intervention: Repeat course of hylan G-F 20
Number of subjects: 255

Group type: COMPARATOR
Intervention: Appropriate care without hylan G-F 20
Number of subjects: 255
Study: 12706743

Group type: EXPERIMENTAL
Intervention: Single dose of diethyl carbamazine citrate (DEC)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: 14 day treatment with diethyl carbamazine citrate (DEC)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control group (non-endemic area)
Number of subjects: 29
Study: 10361567

Group type: EXPERIMENTAL
Intervention: Version M (mainstream drug - Metoprolol)
Number of subjects: 291

Group type: COMPARATOR
Intervention: Version V (unconventional drug - beef spleen cell extract)
Number of subjects: 291
Study: 10150847

Group type: EXPERIMENTAL
Intervention: Nonsteroidal eye drops
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nonsteroidal agents
Number of subjects: 0
Study: 1827622

Group type: EXPERIMENTAL
Intervention: Ketoconazole (200 mg orally for 6 days)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Prednisolone (14.8 mg intravenously)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Pharmacodynamic models
Number of subjects: 6
Study: 7280443

Group type: EXPERIMENTAL
Intervention: Octavalent vaccine (serotypes 1, 3, 6A, 7F, 14, 18C, 19F, and 23F)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Heptavalent control vaccine (serotypes 2, 4, 5, 8, 9N, 12F, and 24F)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Octavalent vaccine
Number of subjects: 124

Group type: COMPARATOR
Intervention: Heptavalent control vaccine
Number of subjects: 124
Study: 30912314

Group type: EXPERIMENTAL
Intervention: Weight-appropriate reusable Masimo probe with Masimo Rad-87 box (M + M)
Number of subjects: 572

Group type: EXPERIMENTAL
Intervention: Lifebox LB-01 probe with Masimo Rad-87 box (L + M)
Number of subjects: 572

Group type: COMPARATOR
Intervention: Lifebox LB-01 probe and Lifebox V1.5 box (L + L)
Number of subjects: 572
Study: 28073339

Group type: EXPERIMENTAL
Intervention: Arm & Hammer™ Sensitive Skin plus Skin‐Friendly Fresh Scent
Number of subjects: 0

Group type: COMPARATOR
Intervention: Arm & Hammer Free & Clear
Number of subjects: 0
Study: 26555595

Group type: EXPERIMENTAL
Intervention: MFO intensity training
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: 60% of VO2-peak intensity training
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Free moderate-intensity at-home exercise
Number of subjects: 136

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 136
Study: 23320544

Group type: EXPERIMENTAL
Intervention: Spice burger (cooked with salt and spice mix)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control burger (cooked with salt only)
Number of subjects: 22
Study: 20720438

Group type: EXPERIMENTAL
Intervention: Diabetic patients with PDR
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Diabetic patients with poor glycemic control
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Patients with PDR receiving panretinal photocoagulation (PRP)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Diabetic patients
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 30
Study: 19117896

Group type: EXPERIMENTAL
Intervention: DTaP(5)‐IPV‐Hib
Number of subjects: 1939

Group type: COMPARATOR
Intervention: Separate vaccines (DTaP(5), IPV, Hib)
Number of subjects: 1939
Study: 17503745

Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate (TDF) associated with atazanavir/ritonavir
Number of subjects: 53
Study: 15214256

Group type: EXPERIMENTAL
Intervention: Lysine-fortified wheat flour
Number of subjects: 80

Group type: COMPARATOR
Intervention: Non-fortified wheat flour
Number of subjects: 80
Study: 12479506

Group type: EXPERIMENTAL
Intervention: TCDD exposure (mean serum concentration between 2.6 and 8.1 ppt)
Number of subjects: 37
Study: 10731737

Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 104

Group type: COMPARATOR
Intervention: Isoflurane
Number of subjects: 104
Study: 9618132

Group type: EXPERIMENTAL
Intervention: Endoscopic pancreatic therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Surgical techniques
Number of subjects: 0
Study: 1895044

Group type: EXPERIMENTAL
Intervention: Enalapril (E), 20 mg d‐1
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Enalapril (E), 40 mg d‐1
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Slow-release verapamil (V), 240 mg d‐1
Number of subjects: 22

Group type: COMPARATOR
Intervention: Quality-of-life questionnaire
Number of subjects: 22
Study: 6193353

Group type: EXPERIMENTAL
Intervention: Intravenous isosorbide dinitrate infusion (50-200 micrograms/kg/h)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Intravenous hydralazine (0.15 mg/kg)
Number of subjects: 20
Study: 31778483

Group type: EXPERIMENTAL
Intervention: X-ray image analysis of seeds with 43% initial water content dried to predetermined levels (43%, 37%, 34%, 31%, and 28%).
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Germination test of seeds after X-ray analysis.
Number of subjects: 200
Study: 30724683

Group type: EXPERIMENTAL
Intervention: HIIT-T
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: HIIT-WB
Number of subjects: 41

Group type: COMPARATOR
Intervention: MICT
Number of subjects: 41
Study: 28877914

Group type: EXPERIMENTAL
Intervention: ICD implantation in patients ≤70 years of age
Number of subjects: 1116

Group type: EXPERIMENTAL
Intervention: ICD implantation in patients >70 years of age
Number of subjects: 1116

Group type: COMPARATOR
Intervention: Comparison of modes of death between age groups
Number of subjects: 1116
Study: 26280945

Group type: EXPERIMENTAL
Intervention: Flavonoid-rich orange juice (240 ml, 272 mg flavonoids)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Calorie-matched placebo
Number of subjects: 0
Study: 24242903

Group type: EXPERIMENTAL
Intervention: Pasireotide 600 µg bid
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Pasireotide 1,950 µg bid
Number of subjects: 112

Group type: COMPARATOR
Intervention: Moxifloxacin (control)
Number of subjects: 112
Study: 22886293

Group type: EXPERIMENTAL
Intervention: Closed-suction drainage (CSD)
Number of subjects: 65

Group type: COMPARATOR
Intervention: No wound drainage (NWD)
Number of subjects: 65
Study: 21060036

Group type: EXPERIMENTAL
Intervention: ULABTKA cream applied to hands and feet twice per day for 21 days after the start of capecitabine
Number of subjects: 137

Group type: COMPARATOR
Intervention: Placebo cream applied to hands and feet twice per day for 21 days after the start of capecitabine
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: ULABTKA cream
Number of subjects: 137

Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 137
Study: 17353985

Group type: EXPERIMENTAL
Intervention: Laparoscopic parastomal hernia repair using a hand‐made 'funnel‐shaped' Gore‐Tex Dual Mesh
Number of subjects: 55

Group type: COMPARATOR
Intervention: Conversion to laparotomy due to dense adhesions or bowel injury
Number of subjects: 55
Study: 16110023

Group type: EXPERIMENTAL
Intervention: Preoperative radiotherapy (25 Gy in 5 days)
Number of subjects: 908
Study: 11860727

Group type: EXPERIMENTAL
Intervention: Usual dietary isoflavone intake (high genistein consumption)
Number of subjects: 208
Study: 9055051

Group type: EXPERIMENTAL
Intervention: Pediatric vaccine with lower protein content than adult vaccine; specific dosage not mentioned.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Adult vaccine (approved); specific dosage not mentioned.
Number of subjects: 0
Study: 8419809

Group type: EXPERIMENTAL
Intervention: Piracetam (2.4-16.8 g daily)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Piracetam
Number of subjects: 21
Study: 3532292

Group type: EXPERIMENTAL
Intervention: Single nighttime dose of 800 mg cimetidine
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 29249365

Group type: EXPERIMENTAL
Intervention: iTBS of the affected motor cortex hand area (n=8)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: 1-Hz stimulation of the unaffected motor cortex hand area (n=7)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Sham stimulation (n=6)
Number of subjects: 21
Study: 27291761

Group type: EXPERIMENTAL
Intervention: Endurance Training (ET)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: High Intensity Interval Training (HIIT)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 60
Study: 25365551

Group type: EXPERIMENTAL
Intervention: UVA/riboflavin corneal collagen cross‐linking (CXL)
Number of subjects: 44
Study: 23059922

Group type: EXPERIMENTAL
Intervention: RME/HG group (banded rapid maxillary expander followed by cervical pull headgear)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: HG group (cervical pull headgear alone)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control group (no active treatment)
Number of subjects: 64
Study: 19568761

Group type: EXPERIMENTAL
Intervention: Local injury to the endometrium on the day of oocyte retrieval
Number of subjects: 156

Group type: COMPARATOR
Intervention: No intervention (Control)
Number of subjects: 156
Study: 18550965

Group type: EXPERIMENTAL
Intervention: Plyometric exercise
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control group (rest)
Number of subjects: 9
Study: 15726320

Group type: EXPERIMENTAL
Intervention: Cementless total hip endoprosthesis (Vision 2000/Duraloc)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Cementless total hip endoprosthesis (ALPHA‐Fit/ALPHA‐Lock Plus)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Cementless total hip endoprosthesis (CLS/Allofit)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Cementless total hip endoprosthesis (Mayo/Trilogy)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Prostheses with shorter stem
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Prostheses with proximally porous coating made from cobalt‐chrome alloy
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Prostheses made from titanium alloy with completely rough‐blasted surface
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Low preoperative corticalis-bone marrow index
Number of subjects: 81
Study: 12205201

Group type: EXPERIMENTAL
Intervention: Interventional paired associative stimulation (IPAS) consisting of repetitive application of single afferent electric stimuli to the right median nerve paired with single pulse transcranial magnetic stimulation (TMS).
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Interventional paired associative stimulation (IPAS) under the influence of dextromethorphan (an NMDA receptor antagonist).
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Double-shock TMS protocol as part of the IPAS.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Suprathreshold test TMS pulse conditioned by a subthreshold TMS pulse delivered 3 ms before the test pulse.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Suprathreshold test TMS pulse conditioned by afferent median nerve stimulation delivered 25 ms before the TMS pulse.
Number of subjects: 0
Study: 10592922

Group type: EXPERIMENTAL
Intervention: Indomethacin and dopamine
Number of subjects: 33

Group type: COMPARATOR
Intervention: Indomethacin alone (control group)
Number of subjects: 33
Study: 8916982

Group type: EXPERIMENTAL
Intervention: Immediate add-back therapy (medrogestone 10 mg/day for 24 weeks)
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Deferred add-back therapy (placebo for 12 weeks followed by medrogestone 10 mg/day for 12 weeks)
Number of subjects: 123

Group type: COMPARATOR
Intervention: Placebo (with Zoladex for 24 weeks)
Number of subjects: 123
Study: 1607464

Group type: EXPERIMENTAL
Intervention: Elastic compression treatment
Number of subjects: 23
Study: 6378211

Group type: EXPERIMENTAL
Intervention: Long-acting propranolol (60 mg once a day)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Conventional propranolol (20 mg three times a day)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Long-acting propranolol (60 mg once a day) after 8 days
Number of subjects: 16

Group type: COMPARATOR
Intervention: Conventional propranolol (20 mg three times a day) after 8 days
Number of subjects: 16

Group type: COMPARATOR
Intervention: Exercise heart rate suppression on Day 1
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Exercise heart rate suppression on Day 8
Number of subjects: 16
Study: 30588619

Group type: EXPERIMENTAL
Intervention: Anastrozole after tamoxifen
Number of subjects: 656
Study: 29650200

Group type: EXPERIMENTAL
Intervention: Arbi Care application (intervention group)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Standard education (control group)
Number of subjects: 120
Study: 26026177

Group type: EXPERIMENTAL
Intervention: Annotation-supplemented telementoring
Number of subjects: 8

Group type: COMPARATOR
Intervention: Verbal mentoring
Number of subjects: 8
Study: 25293888

Group type: EXPERIMENTAL
Intervention: Reminder card sent separately 4 days before the examination (IG3)
Number of subjects: 466

Group type: EXPERIMENTAL
Intervention: Reminder card together with the appointment letter (IG2)
Number of subjects: 466

Group type: COMPARATOR
Intervention: No reminder card (IG1)
Number of subjects: 466

Group type: EXPERIMENTAL
Intervention: Reminder card (any type)
Number of subjects: 466

Group type: EXPERIMENTAL
Intervention: General practitioners (GP) data collection
Number of subjects: 466

Group type: EXPERIMENTAL
Intervention: Influenza vaccination data comparison
Number of subjects: 466
Study: 22389082

Group type: EXPERIMENTAL
Intervention: 135 mg EGCG
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: All treatments (including 135 mg EGCG and placebo)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: 270 mg EGCG
Number of subjects: 27
Study: 20483861

Group type: EXPERIMENTAL
Intervention: 0.5% Polidocanol (POL)
Number of subjects: 316

Group type: EXPERIMENTAL
Intervention: 1% Sodium Tetradecyl Sulphate (STS)
Number of subjects: 316

Group type: COMPARATOR
Intervention: Isotonic Saline (placebo)
Number of subjects: 316
Study: 17297526

Group type: EXPERIMENTAL
Intervention: Spirometry (pre- and post-bronchodilator)
Number of subjects: 818
Study: 16140071

Group type: EXPERIMENTAL
Intervention: Single dose of gemcitabine 2000 mg in 100 mL of unbuffered saline (n = 11)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Twice weekly doses of gemcitabine 2000 mg in 100 mL of unbuffered saline for 3 weeks (n = 11)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Once weekly doses of gemcitabine 2000 mg in 100 mL of unbuffered saline for 6 weeks (n = 10)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Overall treatment with gemcitabine
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Side effects from gemcitabine treatment
Number of subjects: 30
Study: 12040677

Group type: EXPERIMENTAL
Intervention: 0.5 mg CGS20267 (Letrozole) once daily
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: 1.0 mg CGS20267 (Letrozole) once daily
Number of subjects: 41
Study: 9462768

Group type: EXPERIMENTAL
Intervention: 1% lidocaine with hyaluronidase (15 U/cc)
Number of subjects: 25
Study: 7541854

Group type: EXPERIMENTAL
Intervention: Aromatase inhibitor atamestane (400 mg daily for 48 weeks)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study: 2571590

Group type: EXPERIMENTAL
Intervention: Celiprolol
Number of subjects: 12

Group type: COMPARATOR
Intervention: Nifedipine
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Celiprolol + Nitroglycerin
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Celiprolol + Nifedipine
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control (Placebo)
Number of subjects: 12
Study: 60565

Group type: EXPERIMENTAL
Intervention: Single intravenous dose of tobramycin and lincomycin
Number of subjects: 0
Study: 31762179

Group type: EXPERIMENTAL
Intervention: BM odor or taste + heartbeat sounds + non‐nutritive sucking (condition 4)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: BM odor or taste (condition 2)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: BM odor or taste + heartbeat sounds (condition 3)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Routine care (condition 1)
Number of subjects: 140
Study: 31429802

Group type: EXPERIMENTAL
Intervention: Online intervention with personalized normative feedback, cultural engagement content, and strategies to prevent risky sexual behaviors and sexual violence.
Number of subjects: 1200

Group type: EXPERIMENTAL
Intervention: Online intervention
Number of subjects: 1200
Study: 28951372

Group type: EXPERIMENTAL
Intervention: Periodontal intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (gargle solution containing chlorhexidine gluconate)
Number of subjects: 0
Study: 25671683

Group type: EXPERIMENTAL
Intervention: WebQuit.org (web-based ACT for smoking cessation)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Smokefree.gov (control group)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: WebQuit.org
Number of subjects: 94
Study: 22095631

Group type: EXPERIMENTAL
Intervention: Denosumab 60 mg every 6 months
Number of subjects: 7808

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7808
Study: 21092865

Group type: EXPERIMENTAL
Intervention: Visual targets defined in gaze-centered coordinates
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Proprioceptive cues defined in body-centered coordinates
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mixed gaze- and body-centered representation
Number of subjects: 0
Study: 18519128

Group type: EXPERIMENTAL
Intervention: Gallbladder aspiration (group A, n = 80)
Number of subjects: 160

Group type: COMPARATOR
Intervention: No gallbladder aspiration (group C, n = 80)
Number of subjects: 160
Study: 15958649

Group type: EXPERIMENTAL
Intervention: Polyphenon E 400 mg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Polyphenon E 800 mg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Polyphenon E 1200 mg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Polyphenon E (all doses)
Number of subjects: 30
Study: 12653813

Group type: EXPERIMENTAL
Intervention: Lofexidine (0.4, 0.8 and 1.6 mg, p.o.)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Clonidine (0.1 and 0.2 mg, p.o.)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Naloxone (0, 0.1 and 0.3 mg, i.m.)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 10697301

Group type: EXPERIMENTAL
Intervention: losartan
Number of subjects: 16

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 16
Study: 7574011

Group type: EXPERIMENTAL
Intervention: Milrinone 25 micrograms/kg
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Milrinone 50 micrograms/kg
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Milrinone 75 micrograms/kg
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Milrinone (all doses combined)
Number of subjects: 29
Study: 2038654

Group type: EXPERIMENTAL
Intervention: Eutectic mixture of local anaesthetics cream (EMLA) applied to the nasal vestibule
Number of subjects: 25

Group type: COMPARATOR
Intervention: Menthol
Number of subjects: 25
Study: 6161379

Group type: EXPERIMENTAL
Intervention: Home visit
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group (no home visit)
Number of subjects: 18
Study: 29310115

Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Amitriptyline
Number of subjects: 84

Group type: COMPARATOR
Intervention: Control group (healthy controls)
Number of subjects: 84
Study: 25599968

Group type: EXPERIMENTAL
Intervention: Buprenorphine Transdermal System (BTDS) 10 and 20 mcg/hour
Number of subjects: 541

Group type: EXPERIMENTAL
Intervention: Buprenorphine Transdermal System (BTDS) 20 mcg/hour
Number of subjects: 541

Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 541

Group type: COMPARATOR
Intervention: Lower-dose control (BTDS 5 mcg/hour)
Number of subjects: 541
Study: 23742734

Group type: COMPARATOR
Intervention: Written advance directive
Number of subjects: 1962

Group type: COMPARATOR
Intervention: Proxy opinion
Number of subjects: 1962

Group type: COMPARATOR
Intervention: Combination of written advance directive and proxy opinion
Number of subjects: 1962

Group type: COMPARATOR
Intervention: Handwritten directive
Number of subjects: 1962

Group type: COMPARATOR
Intervention: Formalized directive
Number of subjects: 1962

Group type: COMPARATOR
Intervention: Doctor as proxy
Number of subjects: 1962

Group type: COMPARATOR
Intervention: Family member as proxy
Number of subjects: 1962
Study: 22551017

Group type: EXPERIMENTAL
Intervention: Brief advice together with a measurement of exhaled CO (Intervention Group)
Number of subjects: 471

Group type: COMPARATOR
Intervention: Brief advice (Control Group)
Number of subjects: 471
Study: 20728029

Group type: EXPERIMENTAL
Intervention: Bone graft (study group)
Number of subjects: 60

Group type: COMPARATOR
Intervention: No bone graft (control group)
Number of subjects: 60
Study: 19087316

Group type: EXPERIMENTAL
Intervention: Second-look encouragement for loan approval
Number of subjects: 257

Group type: EXPERIMENTAL
Intervention: Access to credit
Number of subjects: 257
Study: 15781537

Group type: COMPARATOR
Intervention: 5 mg standard morphine
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: 10 mg extended-release morphine (EREM)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: 15 mg extended-release morphine (EREM)
Number of subjects: 75
Study: 14723389

Group type: EXPERIMENTAL
Intervention: Anabolic-androgenic steroids
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control (no anabolic-androgenic steroids)
Number of subjects: 23